Show simple item record

dc.contributor.editorLópez, José I.
dc.contributor.editorManini, Claudia
dc.date.accessioned2022-06-21T09:06:53Z
dc.date.available2022-06-21T09:06:53Z
dc.date.issued2022
dc.identifierONIX_20220621_9783036530482_13
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/84579
dc.description.abstractCancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients’ benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: generalen_US
dc.subject.classificationthema EDItEUR::P Mathematics and Science::PN Chemistryen_US
dc.subject.otherbladder cancer
dc.subject.otherradiotherapy
dc.subject.otherradiosensitisation
dc.subject.othermolecular subtypes
dc.subject.otherpreclinical studies
dc.subject.otherbladder cancer cell lines
dc.subject.otherlatent cancer
dc.subject.otherprostate cancer
dc.subject.otherautopsy
dc.subject.otherprognostic index
dc.subject.otherprediction model
dc.subject.othermortality
dc.subject.otherscreening trial
dc.subject.otherrenal cell carcinoma
dc.subject.otherPD-1
dc.subject.otherPD-L1
dc.subject.otherbiomarkers
dc.subject.otherimmune checkpoint inhibitors
dc.subject.otherprostatic neoplasms
dc.subject.otherpositron-emission tomography
dc.subject.otherdecision making
dc.subject.othertumor thrombus
dc.subject.othermetastasectomy
dc.subject.otherpostoperative complications
dc.subject.otheroncological outcomes
dc.subject.otherradical cystectomy
dc.subject.otherAHNAK2
dc.subject.otherprognosis
dc.subject.otherdog
dc.subject.othercomparative oncology
dc.subject.otherinflammation
dc.subject.otherprostatic atrophy
dc.subject.otherpreneoplastic lesion
dc.subject.otherbiomarker
dc.subject.otherurine
dc.subject.othermachine learning
dc.subject.otherTRIPOD
dc.subject.otherliquid biopsy
dc.subject.otherglutaminase
dc.subject.otherimmunohistochemistry
dc.subject.otherin situ methods
dc.subject.otherprostate
dc.subject.otherPSMA-RLT
dc.subject.other177Lu-PSMA
dc.subject.otherPSA
dc.subject.othermCRPC
dc.subject.otherurinary bladder neoplasms
dc.subject.otherBacillus Calmette–Guérin (BCG)
dc.subject.otherimmunotherapy
dc.subject.otherdivergent differentiation
dc.subject.othervariant morphology
dc.subject.othersurvival
dc.subject.otherstereotactic body radiotherapy
dc.subject.otherfrail patients
dc.subject.othercancer
dc.subject.othermetastasis
dc.subject.othergenomic analysis
dc.subject.othermicroenvironment
dc.subject.othertumor ecology
dc.subject.othergame theory
dc.subject.otherfluorescence confocal microscopy
dc.subject.otherprostate biopsy
dc.subject.otherablation margins
dc.subject.otherfocal therapy
dc.subject.othersphingosine 1-phosphate receptor 1
dc.subject.otherbladder carcinoma
dc.subject.othercell migration
dc.subject.otherepithelial–mesenchymal transition
dc.subject.otherFTY-720
dc.subject.otherOIP5
dc.subject.otherpapillary renal cell carcinoma
dc.subject.otherPLK1
dc.subject.othertumorigenesis
dc.subject.othertherapy
dc.subject.otherimage-guided
dc.subject.othermagnetic resonance imaging
dc.subject.otherultrasonography
dc.subject.otherbiopsy
dc.subject.otherabiraterone
dc.subject.otherenzalutamide
dc.subject.otherdocetaxel
dc.subject.othernovel hormonal therapies
dc.subject.othercomparative effectiveness
dc.subject.otherreal-world treatment pattern
dc.subject.othermetastatic prostate cancer
dc.subject.otherepiplakin
dc.subject.otherdiagnosis
dc.subject.otheradvanced urothelial carcinoma
dc.subject.otherimmune checkpoint inhibitor
dc.subject.otherprognostic
dc.subject.othertumour mutational board
dc.subject.othergenomic signatures
dc.subject.otherctDNA
dc.subject.otherinflammatory indices
dc.subject.otherurothelial carcinoma
dc.subject.otherfrailty
dc.subject.otherprognostic factor
dc.subject.otherpsoas muscle
dc.subject.otherHounsfield units
dc.subject.othern/a
dc.titleUrological Cancer 2021
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-3049-9
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036530482
oapen.relation.isbn9783036530499
oapen.pages328


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/